Fate Therapeutics Inc (FATE)

Precedente Chiudi:

$3.87

Aprire:

$3.88

Volume 24 ore:

2.73M

Capitalizzazione di mercato:

$432.38M

Reddito:

$63.53M

Utile/perdita netta:

$-160.93M

Rapporto P/E:

-1.7512

EPS:

-2.17

Flusso di cassa netto:

$-138.42M

1 W Prestazione:

-20.67%

1M Prestazione:

-44.61%

6M Prestazione:

+117.14%

1 anno Prestazione:

-34.71%

Intervallo 1D:

$3.74

$3.95

Portata 52W:

$1.63

$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

Nome

Fate Therapeutics Inc

Settore

Healthcare (1191)

Industria

Biotechnology (688)

Telefono

858-875-1800

Indirizzo

3535 General Atomics Court, Suite 200, San Diego, CA

Dipendente

80

Cinguettio

@fatethx

Prossima data di guadagno

2024-05-01

Ultimi documenti SEC

FATE's Discussions on Twitter

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-03-27	Ripresa	Wells Fargo	Equal Weight
2023-01-24	Downgrade	H.C. Wainwright	Buy → Neutral
2023-01-06	Downgrade	BMO Capital Markets	Outperform → Market Perform
2023-01-06	Downgrade	BofA Securities	Buy → Underperform
2023-01-06	Downgrade	Cowen	Outperform → Market Perform
2023-01-06	Downgrade	Piper Sandler	Overweight → Neutral
2023-01-06	Downgrade	Stifel	Buy → Hold
2023-01-06	Downgrade	Truist	Buy → Hold
2023-01-06	Downgrade	Wedbush	Outperform → Neutral
2023-01-03	Downgrade	Guggenheim	Buy → Neutral
2022-12-22	Downgrade	Oppenheimer	Outperform → Perform
2022-12-15	Iniziato	Goldman	Sell
2022-11-04	Ripresa	Cantor Fitzgerald	Overweight
2022-10-10	Iniziato	Canaccord Genuity	Buy
2022-08-18	Ripresa	Wells Fargo	Overweight
2022-07-28	Iniziato	Needham	Hold
2022-07-11	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2022-06-03	Iniziato	Robert W. Baird	Neutral
2022-02-11	Ripresa	BMO Capital Markets	Market Perform
2021-12-15	Aggiornamento	Wedbush	Neutral → Outperform
2021-12-07	Iniziato	Cowen	Outperform
2021-11-09	Aggiornamento	Citigroup	Neutral → Buy
2021-08-26	Iniziato	Morgan Stanley	Equal-Weight
2021-06-07	Aggiornamento	H.C. Wainwright	Neutral → Buy
2021-05-07	Aggiornamento	Wedbush	Neutral → Outperform
2021-04-26	Ripresa	Jefferies	Buy
2021-02-26	Iniziato	BofA Securities	Buy
2021-02-26	Downgrade	Wedbush	Outperform → Neutral
2021-02-11	Downgrade	Citigroup	Buy → Neutral
2021-01-27	Ripresa	H.C. Wainwright	Neutral
2020-05-13	Iniziato	H.C. Wainwright	Buy
2020-03-04	Iniziato	Barclays	Overweight
2020-01-09	Downgrade	BMO Capital Markets	Outperform → Market Perform
2019-12-30	Reiterato	Mizuho	Buy
2019-12-09	Aggiornamento	Wells Fargo	Market Perform → Outperform
2019-11-12	Iniziato	SunTrust	Buy
2019-11-06	Downgrade	Wells Fargo	Outperform → Market Perform
2019-10-01	Iniziato	Stifel	Buy
2019-08-09	Iniziato	BTIG Research	Buy
2019-07-22	Iniziato	Cantor Fitzgerald	Overweight
2019-07-12	Iniziato	Oppenheimer	Outperform
2019-06-13	Iniziato	Mizuho	Buy
2019-06-07	Iniziato	ROTH Capital	Neutral
2019-05-31	Iniziato	Guggenheim	Buy
2019-05-24	Ripresa	Citigroup	Buy
2019-03-28	Iniziato	SVB Leerink	Outperform
2019-01-03	Downgrade	Stephens	Overweight → Equal-Weight
2018-11-05	Iniziato	Jefferies	Buy
2018-08-01	Iniziato	Citigroup	Buy
2018-03-06	Downgrade	H.C. Wainwright	Buy → Neutral

Mostra tutto

Fate Therapeutics Inc Borsa (FATE) Ultime notizie

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

GlobeNewswire Inc.

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Zacks Investment Research

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

Zacks Investment Research

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know

Zacks Investment Research

Novartis (NVS) to Report Q1 Earnings: What to Expect?

Zacks Investment Research

What's in Store for Biogen (BIIB) This Earnings Season?

Zacks Investment Research

Fate Therapeutics Inc Azioni (FATE) Dati Finanziari

Fate Therapeutics Inc (FATE) Reddito 2024

Fate Therapeutics Inc (FATE) Reddito netto 2024

Fate Therapeutics Inc (FATE) Flusso di cassa 2024

Fate Therapeutics Inc (FATE) Utile per azione 2024